FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2566958034> ?p ?o ?g. }

• W2566958034 endingPage "4603" @default.
• W2566958034 startingPage "4603" @default.
• W2566958034 abstract "4603 Background: There is currently no effective adjuvant therapy available for subjects with advanced RCC. ABT-751, an oral antimitotic agent that binds to the colchicine site of β-tubulin and prevents microtubule polymerization, has shown antitumor activity in various human xenograft models. In addition, signs of antitumor activity, consisting mainly of stable disease, were seen in subjects with RCC during phase 1 ABT-751 studies. Methods: This phase 2, open label, multi-center study evaluated safety and efficacy of ABT-751 in subjects with advanced RCC [N = 97: 43 subjects with no prior therapy (NPT), 54 subjects with prior therapy (PT)]. For each cycle, subjects received 200 mg ABT-751 orally once daily for 21 consecutive days followed by a 7-day break. Cycles were repeated until the subject met discontinuation criteria. Safety was assessed by adverse events (AEs) and laboratory evaluations. Time to progression (TTP) was analyzed using Kaplan-Meier methodology. Tumor response was assessed radiographically every 2 cycles using RECIST. Results: The median duration of therapy was 2 cycles (range 1 - 10). AEs were reported in 94/97 subjects, and 31/97 (32%) subjects experienced serious adverse events (SAEs). The most commonly reported AEs were asthenia (69%), constipation (59%), nausea (46%), and anorexia (44%). The most common Grade 3 or 4 AEs considered possibly or probably related to drug were asthenia (7%) and ileus (7%). The most common SAEs were carcinoma (6%) and ileus (6%). Thirteen subjects experienced SAEs considered possibly related to study drug, and the most common were ileus (5%) and diarrhea (2%). The median TTP was 3.8 months (95% CI = 3.6 - 4.1). One partial response was observed, and the subject is ongoing in Cycle 9. Two other subjects are experiencing minor responses (26% and 22% decrease in target lesions; ongoing in Cycles 6 and 9, respectively). To date, 17 subjects have had stable disease for 8 or more cycles (12 NPT and 5 PT), the longest duration being nearly one year. Conclusions: The 21-day dosing regimen appears to have an acceptable safety profile in phase 2 clinical trials. Prolonged stable disease and tumor responses suggest a potential benefit from ABT-751 therapy. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Abbott Laboratories Abbott Laboratories" @default.
• W2566958034 created "2017-01-06" @default.
• W2566958034 creator A5002322715 @default.
• W2566958034 creator A5012241694 @default.
• W2566958034 creator A5030332656 @default.
• W2566958034 creator A5030964205 @default.
• W2566958034 creator A5050649350 @default.
• W2566958034 creator A5056842097 @default.
• W2566958034 creator A5075566772 @default.
• W2566958034 creator A5087681444 @default.
• W2566958034 creator A5015396359 @default.
• W2566958034 date "2005-06-01" @default.
• W2566958034 modified "2023-09-27" @default.
• W2566958034 title "Preliminary phase 2 results of ABT-751 in subjects with advanced renal cell carcinoma (RCC)" @default.
• W2566958034 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.4603" @default.
• W2566958034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/27946968" @default.
• W2566958034 hasPublicationYear "2005" @default.
• W2566958034 type Work @default.
• W2566958034 sameAs 2566958034 @default.
• W2566958034 citedByCount "5" @default.
• W2566958034 countsByYear W25669580342020 @default.
• W2566958034 crossrefType "journal-article" @default.
• W2566958034 hasAuthorship W2566958034A5002322715 @default.
• W2566958034 hasAuthorship W2566958034A5012241694 @default.
• W2566958034 hasAuthorship W2566958034A5015396359 @default.
• W2566958034 hasAuthorship W2566958034A5030332656 @default.
• W2566958034 hasAuthorship W2566958034A5030964205 @default.
• W2566958034 hasAuthorship W2566958034A5050649350 @default.
• W2566958034 hasAuthorship W2566958034A5056842097 @default.
• W2566958034 hasAuthorship W2566958034A5075566772 @default.
• W2566958034 hasAuthorship W2566958034A5087681444 @default.
• W2566958034 hasConcept C126322002 @default.
• W2566958034 hasConcept C141071460 @default.
• W2566958034 hasConcept C197934379 @default.
• W2566958034 hasConcept C2777125728 @default.
• W2566958034 hasConcept C2777472916 @default.
• W2566958034 hasConcept C2778715236 @default.
• W2566958034 hasConcept C2780580376 @default.
• W2566958034 hasConcept C2781112942 @default.
• W2566958034 hasConcept C71924100 @default.
• W2566958034 hasConcept C90924648 @default.
• W2566958034 hasConceptScore W2566958034C126322002 @default.
• W2566958034 hasConceptScore W2566958034C141071460 @default.
• W2566958034 hasConceptScore W2566958034C197934379 @default.
• W2566958034 hasConceptScore W2566958034C2777125728 @default.
• W2566958034 hasConceptScore W2566958034C2777472916 @default.
• W2566958034 hasConceptScore W2566958034C2778715236 @default.
• W2566958034 hasConceptScore W2566958034C2780580376 @default.
• W2566958034 hasConceptScore W2566958034C2781112942 @default.
• W2566958034 hasConceptScore W2566958034C71924100 @default.
• W2566958034 hasConceptScore W2566958034C90924648 @default.
• W2566958034 hasIssue "16_suppl" @default.
• W2566958034 hasLocation W25669580341 @default.
• W2566958034 hasOpenAccess W2566958034 @default.
• W2566958034 hasPrimaryLocation W25669580341 @default.
• W2566958034 hasRelatedWork W2050621665 @default.
• W2566958034 hasRelatedWork W2054599278 @default.
• W2566958034 hasRelatedWork W2097211888 @default.
• W2566958034 hasRelatedWork W2104761597 @default.
• W2566958034 hasRelatedWork W2362740208 @default.
• W2566958034 hasRelatedWork W2374190337 @default.
• W2566958034 hasRelatedWork W2971476881 @default.
• W2566958034 hasRelatedWork W3007321116 @default.
• W2566958034 hasRelatedWork W3166323315 @default.
• W2566958034 hasRelatedWork W2183331092 @default.
• W2566958034 hasVolume "23" @default.
• W2566958034 isParatext "false" @default.
• W2566958034 isRetracted "false" @default.
• W2566958034 magId "2566958034" @default.
• W2566958034 workType "article" @default.